Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-025-67508-8
Affiliations:
3
Authors:
10
Go to article
Institutions Authors Share
National Center for Cancer Immune Therapy (CCITdk), Denmark
7.500000
 0.75
IO Biotech ApS, Denmark
1.500000
 0.15
Rigshospitalet, Denmark
1.000000
 0.10
Interested in Oncology and Carcinogenesis?